Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Tribune News Service
Tribune News Service
National
Tim Loh

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Giving 8 milligrams of the drug, Eylea, continued to protect patients from developing vision problems even as they received injections every 16 weeks, Bayer said in a statement on Saturday.

The trials included people suffering from two forms of eye disease that involve blood vessel malfunction. The 8-milligram dosing is being studied in comparison with patients who receive standard 2-milligram doses of Eylea on a more frequent basis.

This latest round of data expands on Bayer’s previous statement on the matter from September. The companies are hoping to extend the patent for the aging therapy and fend off competition from Roche’s newcomer Vabysmo.

One trial tested Eylea in people with wet age-related macular degeneration. The other focused on patients with an eye disorder brought on by diabetes.

Regeneron posted $5.8 billion in sales for Eylea last year in the U.S., while Germany-based Bayer — which markets the drug in the rest of the world — had revenue of 4.7 billion euros ($4.67 billion).

(Rainer Buergin contributed.)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.